Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Other 1Lymphoid 1

Conditions

Colorectal Neoplasms 442Rectal Neoplasms 209Colonic Neoplasms 202Pancreatic Neoplasms 133Stomach Neoplasms 117Neoplasm Metastasis 86Esophageal Neoplasms 57Carcinoma, Hepatocellular 41Adenocarcinoma Of Esophagus 37Neoplasms 36Cholangiocarcinoma 27Biliary Tract Neoplasms 23Gastrointestinal Neoplasms 20Gallbladder Neoplasms 20Adenocarcinoma 19Carcinoma, Non-Small-Cell Lung 16Esophageal Squamous Cell Carcinoma 15Liver Neoplasms 14Bile Duct Neoplasms 14Digestive System Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Colorectal Cancer Metastatic 8Appendiceal Neoplasms 7Peritoneal Neoplasms 6Ovarian Neoplasms 6Intestinal Neoplasms 6Carcinoma 6Breast Neoplasms 6Lung Neoplasms 5Carcinoma, Renal Cell 5

Interventions

Oxaliplatin 6Sodium Chloride 3Leucovorin 3Fluorouracil 3xaliproden 2Magnesium Sulfate 2Folfox protocol 2Calcium Gluconate 2neurotropin 1Pharmacogenomic Testing 1Gene Expression Profiling 1Capecitabine 1Bevacizumab 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neurotoxicity Syndromes × Leucovorin × Gastrointestinal × Clear all
NCT01279681 2017-12-08

Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Terminated
32 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Neurotoxicity Syndromes

NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

NCT00884767 2009-07-08

Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

National Cancer Institute (NCI)

Phase 2 Unknown
206 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡